Avantium appoints bioplastics specialist
Jeffrey Kolstad joins as chief scientist from NatureWorks
Previously chief scientist at NatureWorks (formerly Cargill-Dow), Kolstad was one of the founding members of the team that developed and commercialised PLA (polylactic-acid), a bio-based polymer. He was also responsible for managing NatureWorks’ IP portfolio and strategy.
Prior to this Kolstad worked in the corporate research centres at Cargill and Amoco Oil Company.
You may also like
Research & Development
€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment
The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response
The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models
Research & Development
Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research
The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases